UPDATE: Dawson James Reiterates Agenus Inc. at Buy After Rapid Phase II Trial Enrollment on HerbV

In a report published by Dawson James, analyst Robert M. Wasserman reiterated a Buy rating and $6.00 price target on Agenus, Inc.

Dawson James reported that, “Key developments for the fourth quarter for Agenus included the November publication of the second complete results from the Phase 3 trial of GSK's malaria vaccine candidate and the start of a Phase 2 multicenter study of HerpV for the treatment of genital herpes in HSV-2 positive subjects. Subsequent to year-end, Agenus completed enrollment in this Phase 2 HerpV viral shedding study, with results expected to be released by the end of this year.” Shares of Agenus, Inc. closed at $4.46 on Monday.